Replies to post #255 on C4 Therapeutics Inc (CCCC)

[B RY]

Jan 29, 2024. "JP Morgan upgraded C4 Therapeutics (NASDAQ:CCCC) to neutral, citing its improved pipeline outlook.

The investment bank said it was upgrading the stock after taking a “deeper look” at data released in December from a Phase 1 study for CFT7455, “having gained more comfort with the case for differentiation from key IMiD/CELMoD competitors, namely mezigdomide.”

JP Morgan said if the company can provide a sustained case for differentiation over mezigdomide with additional data readouts, it sees the drug “being a strategically attractive complement to existing multiple myeloma franchises.”

The bank said that it based the upgrade on its “cautiously optimistic CFT7455 outlook along with initial promising data for CFT1946 in BRAFi resistant tumors,” which offers “additional pipeline optionality.”
https://seekingalpha.com/news/4059658-jp-morgan-upgrades-c4-therapeutics-to-neutral-cites-pipeline

[B RY]

Researching pharmaceutical technologies is my favorite reading subs. Trading stocks for a nicely growing income in my living trust to help others when I pass away is motivating to me. If a doctor informs me I have a specific medical condition as I get older, I feel comfortable with my knowledge of going after the best manner to make a difference in it's early stages. Making early corrections is the difference in your longevity. Knowledge is the key!